The Phase I clinical trial is expected to enrol approximately nine to 12 LN patients across the US.
Findings from the trial showed that the treatment with ADX-2191 significantly improved retinal function.
Mite eradication and complete collarette cure are the co-primary endpoints of the trial.
The trial will assess the pharmacokinetics, pharmacodynamics, tolerability, and safety of AZ-3102 across two doses.
The Tagrisso and chemotherapy combination therapy showed strong improvement in progression-free survival.
Give your business an edge with our leading industry insights.
The trial will assess four MM-120 doses to treat anxiety symptoms in GAD diagnosed patients.
The trial will assess three different dose levels of G-NK cells alone and along with interleukin-2 and the monoclonal antibodies.
The first Phase Ib trial will assess the tolerability and safety of neoadjuvant use of intratumorally injected PH-762.
The trial will assess the intravesical TARA-002 at the 40KE dose in 12 patients with CIS.
The trial will confirm the efficacy of the drug candidate for the treatment of cutaneous warts.